Cartesian Therapeutics (RNAC) Leases (2018 - 2025)
Historic Leases for Cartesian Therapeutics (RNAC) over the last 8 years, with Q3 2025 value amounting to $5.0 million.
- Cartesian Therapeutics' Leases fell 6323.3% to $5.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.0 million, marking a year-over-year decrease of 6323.3%. This contributed to the annual value of $5.5 million for FY2024, which is 4502.38% down from last year.
- As of Q3 2025, Cartesian Therapeutics' Leases stood at $5.0 million, which was down 6323.3% from $5.2 million recorded in Q2 2025.
- Over the past 5 years, Cartesian Therapeutics' Leases peaked at $13.9 million during Q2 2024, and registered a low of $3.2 million during Q4 2022.
- Moreover, its 5-year median value for Leases was $10.1 million (2023), whereas its average is $9.2 million.
- In the last 5 years, Cartesian Therapeutics' Leases plummeted by 6744.33% in 2022 and then skyrocketed by 21462.5% in 2023.
- Over the past 5 years, Cartesian Therapeutics' Leases (Quarter) stood at $9.8 million in 2021, then crashed by 67.44% to $3.2 million in 2022, then skyrocketed by 214.63% to $10.1 million in 2023, then crashed by 45.02% to $5.5 million in 2024, then fell by 10.17% to $5.0 million in 2025.
- Its last three reported values are $5.0 million in Q3 2025, $5.2 million for Q2 2025, and $5.4 million during Q1 2025.